Clinical Trial Authorisation

18 April 2008 – We are pleased to inform shareholders that a Clinical Trial Authorisation has been obtained from the relevant European competent authority for a trial of AIMSPRO in a major rheumatological disorder.

This Authorisation follows five years of focused Research and Development, as well as open-label observations in a number of "compassionate basis" patients with a range of medical conditions. The evidence showed very clearly that formal trialing of AIMSPRO as a general anti-inflammatory agent should be pursued as energetically as regulatory approvals would allow.

Meanwhile, pre-clinical studies of Daval's veterinary product Ceremben are being carried out at three Australian universities and these will be complete well before the end of this year.


More News